SCHEMBL21629564

SCHEMBL21629564

CC(C)(C)OC(=O)COc1ccc2c(-c3ccccc3)cc(=O)oc2c1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.74
ALDH1A1 P00352 8/20 0.74
USP2 O75604 1/20 0.74
SMN1; SMN2 Q16637 2/20 0.73
KMT2A Q03164 2/20 0.68
MAOB P27338 1/20 0.61
KDM4E B2RXH2 2/20 0.60
LMNA P02545 2/20 0.60
RAB9A P51151 3/20 0.58
CYP1A2 P05177 1/20 0.58
GAA P10253 1/20 0.58
CYP2C19 P33261 1/20 0.58
CA9 Q16790 1/20 0.57
NPC1 O15118 1/20 0.57
TNF P01375 1/20 0.57
POLB P06746 1/20 0.57
NOD1 Q9Y239 1/20 0.57
TDP1 Q9NUW8 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21629622 0.86 ALDH1A1 (0.83) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21630150 0.85 HPGD (1.00) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21629627 0.84 ALDH1A1 (0.83) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21629515 0.83 ALDH1A1 (0.72) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21629528 0.83 ALDH1A1 (0.81) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21629549 0.83 HPGD (0.82) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21629538 0.82 HPGD (0.70) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21629537 0.81 ALDH1A1 (1.00) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21629529 0.80 TDP1 (0.82) HPGDALDH1A1USP2SMN1; SMN2KMT2A
SCHEMBL21629629 0.80 ALDH1A1 (0.76) HPGDALDH1A1USP2SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 US claimed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 US claimed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 US claimed
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 US disclosed
EP-4333822-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION Lead Discovery Center GmbH (DE) 2024-03-13 EP disclosed
WO-2022233782-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2022-11-10 WO disclosed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 US disclosed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 US disclosed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 US disclosed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 US disclosed
EP-3598972-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-01-29 EP disclosed
EP-3598972-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION TFAM, POLRMT, TUFM HPGD 1853/4885ALDH1A1 3415/4885USP2 2506/4885
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER POLRMT, COX4I1, UQCRC2 HPGD 1377/4885ALDH1A1 1344/4885USP2 3352/4885
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer POLRMT, COX4I1, UQCRC2 HPGD 1377/4885ALDH1A1 1344/4885USP2 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.